Trending on the Timeline: Ozempic Faces Lawsuits Over Side Effects
The weight loss drug that had everyone talking is now making headlines for all the wrong reasons. Ozempic, originally designed for diabetes management, became the go-to solution for rapid weight loss—but now it's facing serious legal trouble.
Over 1,800 lawsuits have been filed against Novo Nordisk, the company behind Ozempic. People are claiming the drug caused severe side effects that weren't properly disclosed. We're talking about stomach paralysis, intestinal blockage, vision loss, and kidney damage. These aren't minor inconveniences—these are life-altering complications that have people fighting for their health and their rights.
If the courts find Novo Nordisk liable, the payouts could reach a staggering $2 billion. That's billion with a 'B,' y'all. When that many zeros are involved, you know the situation is serious.
We care about your data. See our privacy policy.
Novo Nordisk isn't backing down without a fight. They're denying any wrongdoing and maintaining that Ozempic is safe when prescribed properly by healthcare professionals. But with nearly 2,000 people saying otherwise, that defense is getting harder to maintain.
This whole situation raises a critical point: Is chasing the latest weight loss trend worth risking your long-term health? Social media made Ozempic look like a miracle solution, but real life is showing us the potential consequences.
Before jumping on any health trend, especially one involving prescription medications, consult with your doctor. Your body is the only one you get, so treat it with the respect it deserves. Sometimes the scenic route to your goals is safer than the shortcut.
Stay informed, stay safe, and always prioritize your health over trends.
SEE ALSO
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
1 Reason to Buy NVO
Key Points It is clearly very effective at developing drugs. Its Wegovy recently earned FDA approval for a new indication. 10 stocks we like better than Novo Nordisk › It's one thing for a pharmaceutical company to have a blockbuster drug in its portfolio. It's quite another if such a product can be successfully extended to win approvals for other indications. This is one huge reason to believe in the future of Novo Nordisk (NYSE: NVO), the Danish company behind the immensely popular Wegovy obesity treatment. Last week the company earned a new feather in its cap with the product, and it feels as if it has far more distance to go with drug discovery. Wegovy has legs In mid-August the company hit paydirt when the U.S. Food and Drug Administration (FDA) approved it as a treatment for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adult patients with moderate to advanced liver fibrosis. The drug is intended to be used in combination with an increase in physical activity, and a reduction in caloric food intake. It probably goes without saying that America's obesity problem affects far more individuals than does MASH. But Novo Nordisk's successful development of the drug to treat the liver disorder demonstrates two very positive things; 1) Wegovy (and by extension its sibling medication, Ozempic) has the potential to treat numerous other afflictions and, 2) generally, the company is adept at developing its molecules for a variety of indications. Pipeline to greater success? Novo Nordisk has quite the impressively wide pipeline, and semaglutide (the molecule which is the primary ingredient of Wegovy and Ozempic) is only one part of it. It's in the later stages of investigating the drug for treatment of Alzheimer's; meanwhile, it's got a host of other molecules in programs aimed in many therapeutic directions. With such a high pitch of activity, the future is bright for semaglutide and other investigational drugs. And, by extension, their developer. Should you buy stock in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 1 Reason to Buy NVO was originally published by The Motley Fool
Newsweek
4 hours ago
- Newsweek
Californians Warned of 'Devastating' New Health Insurance Costs
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Health insurance costs are set to increase for Californians in 2026, and the state's health insurance marketplace has warned that the impacts could be a major burden on American families. This comes as health insurance premiums are expected to rise significantly across the country next year, when enhanced tax credits are set to expire, as President Donald Trump has not chosen to renew them. A spokesperson for Covered California told Newsweek: "The combined impact of the premium increases and the loss of enhanced premium tax credits would be devastating for Californians." "All Covered California enrollees would face higher costs, and the loss of enhanced tax credits alone could result in an average net premium increase of 66 percent for 1.7 million enrollees," they said. The spokesperson called it "a catastrophic financial burden for many, potentially pricing a significant number of individuals and families out of coverage." "Those with the lowest incomes would be hit hardest, as stagnant wages and rising inflation amplify their challenges." Why It Matters Aside from the expiration of enhanced tax credits, which will see 2026's rise in costs jump much higher than previous years, there are also a number of other factors pushing up premiums. These factors include increased health care costs, inflation, labor costs, and rising demand for medications such as GLP-1 drugs like Ozempic and Wegovy, which are driving up prescription drug spending. While premiums have been steadily increasing over the years, 2026 will see the largest hike in prices since 2018, according to KFF data. Agents help sign people up for insurance through the Covered California exchange at their storefront in Huntington Beach, California. Agents help sign people up for insurance through the Covered California exchange at their storefront in Huntington Beach, California. Nick Agro/The Orange County Register via AP What To Know Covered California recently announced that it would be increasing rates for health coverage in 2026 by an average of 10.3 percent across various health plans. Those on Affordable Care Act (ACA)-compliant plans will be affected, as the temporary subsidies for ACA marketplaces, introduced by former President Joe Biden to increase access to health coverage, will expire at the end of 2025. While there is still time for the Trump administration to opt to extend the subsidies, there has been no indication yet by the administration that they intend to, and the subsidies also come at a significant cost to the taxpayer. Covered California told Newsweek that its planned 10.3 percent increase is lower than the national average of 20 percent, with states like Florida having much higher proposed increases. The reason for the state marketplace's increase in premium costs is driven by several factors, the Covered California spokesperson told Newsweek, pointing to "rising health care and pharmacy costs, as well as broader industry challenges." They said that federal health care policies were also "contributing to these increases, particularly the expiration of federal enhanced premium tax credits at the end of 2025." "These credits have helped millions of Americans lower their premiums since 2021, and their expiration will have significant consequences for affordability nationwide," they said. The state marketplace previously said that Congress could reduce these price hikes for Americans by extending the enhanced tax credits, and that it hoped lawmakers on both sides of the aisle "recognize the need to extend this essential lifeline for working families." What People Are Saying A spokesperson for Covered California told Newsweek: "To mitigate these impacts, California is taking proactive steps to shield its lowest-income enrollees from steep increases. For 2026, the state has allocated $190 million from its cost-sharing reduction program to provide state subsidies for individuals earning up to 150 percent of the federal poverty level, helping keep premiums comparable to 2025 levels. "This assistance will benefit individuals with annual incomes of $23,475 or less and families of four earning up to $48,225. Additional support will also be available to those earning up to 165 percent of the federal poverty level." Jonathan Gruber, a professor of economics at Massachusetts Institute of Technology, told Newsweek: "Rates are certainly going to go up because of two changes: the [One Big Beautiful Bill] kicks some folks off exchanges and makes it harder for others to enroll and the additional subsidies that President Biden added to the exchanges are going to expire. When these changes happen it is the healthiest folks who will drop out of the exchanges, raising premiums for everyone else." He added, "This is disastrous for both economic security and health. Studies have shown that losing insurance is associated with enormous economic risk and worse health, including death." Ge Bai, a professor of health policy and management at Johns Hopkins Bloomberg School of Public Health, Maryland, told Newsweek: "ACA-compliant plans have always been expensive, but the federal government has made them appear affordable through taxpayer subsidies. The premiums we see now reflect their actual unaffordability, rather than the artificial affordability created by subsidies." She said: "While market characteristics may cause some state-to-state variations, the overall trend will be upward everywhere because the regulatory constraints driving up costs apply to ACA-compliant plans in all states." "ACA-compliant plans will become more expensive, especially for higher-income beneficiaries who lose subsidy eligibility. We urgently need to address the ACA's regulatory constraints that block affordable plans, rather than pouring taxpayer dollars into creating the illusion of affordability and worsening these plans' true unaffordability." What Happens Next The proposed increases are for the 2026 calendar year, and many are concerned about the impacts they will have on Americans.
Yahoo
8 hours ago
- Yahoo
Ozempic creator Novo Nordisk will sell weight loss drugs for cheaper through this new partnership
Ozempic creator Novo Nordisk will sell weight loss drugs for cheaper through this new partnership originally appeared on TheStreet. Telemedicine company GoodRx () has been helping Americans find the cheapest way to buy drugs for years. Thanks to a new partnership with pharma giant Novo Nordisk () , the creator of Ozempic and Wegovy, it might soon be the cheapest way to buy branded weight loss drugs too. On Monday, the two firms announced a partnership which will allow patients with a prescription to get the branded medication for $499/mo, so long as they're willing to pay out of pocket and present the GoodRx coupon at their local pharmacy. At $499/mo the branded drug is only a little more expensive than compounded GLP-1 injectables sold by telehealth pharmacies, which have drawn the ire of pharmaceutical giants and the Food and Drug Administration (FDA). It's also more expensive than the $349/mo single-dose vial of Zepbound, the competing GLP-1 drug sold by competitor Eli Lilly () , which is also available through GoodRx. However, Ozempic and Wegovy's patented pens might be reason enough to pay up, since they're easier to use. Still, those with insurance might be eligible to have the cost completely covered, rather than pay the out of pocket cost. For that, patients should check with their prescriber and insurer. This is not Novo's first ride on the direct-to-consumer wagon. In April, it partnered with Hims & Hers HIMS (-1%) to help them sell Wegovy directly to customers. Novo ended that effort in July, alleging that the telehealth company intentionally undercut their branded medications through "deceptive promotion and selling of illegitimate, knockoff versions" of its drug, which "put patient safety at risk." A lawsuit has been filed against Hims & Hers. The failed "collaboration" between the companies spurred the departure of its chief executive, as well as a reduction to the company's annual guidance ahead of its quarterly earnings. Worst of all, it say Novo Nordisk lose market share to competitor Eli Lilly, which represents over half of the GLP-1 market. Novo's leadership have indicated a desire to expand its direct-to-consumer offerings and cut prices, looking to undercut both branded and compounded GLP-1 drugs. Ozempic creator Novo Nordisk will sell weight loss drugs for cheaper through this new partnership first appeared on TheStreet on Aug 18, 2025 This story was originally reported by TheStreet on Aug 18, 2025, where it first appeared.
